These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32005942)

  • 1. A bispecific IgG format containing four independent antigen binding sites.
    Ljungars A; Schiött T; Mattson U; Steppa J; Hambe B; Semmrich M; Ohlin M; Tornberg UC; Mattsson M
    Sci Rep; 2020 Jan; 10(1):1546. PubMed ID: 32005942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
    Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
    Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific antibody derivatives based on full-length IgG formats.
    Grote M; Haas AK; Klein C; Schaefer W; Brinkmann U
    Methods Mol Biol; 2012; 901():247-63. PubMed ID: 22723106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G
    De Nardis C; Hendriks LJA; Poirier E; Arvinte T; Gros P; Bakker ABH; de Kruif J
    J Biol Chem; 2017 Sep; 292(35):14706-14717. PubMed ID: 28655766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
    Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
    J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.
    Klein C; Sustmann C; Thomas M; Stubenrauch K; Croasdale R; Schanzer J; Brinkmann U; Kettenberger H; Regula JT; Schaefer W
    MAbs; 2012; 4(6):653-63. PubMed ID: 22925968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The eIg technology to generate Ig-like bispecific antibodies.
    Kühl L; Aschmoneit N; Kontermann RE; Seifert O
    MAbs; 2022; 14(1):2063043. PubMed ID: 35427197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity.
    Shi SY; Lu YW; Liu Z; Stevens J; Murawsky CM; Wilson V; Hu Z; Richards WG; Michaels ML; Zhang J; Yan W; Li Y
    J Biol Chem; 2018 Apr; 293(16):5909-5919. PubMed ID: 29483191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TriFabs--Trivalent IgG-Shaped Bispecific Antibody Derivatives: Design, Generation, Characterization and Application for Targeted Payload Delivery.
    Mayer K; Baumann AL; Grote M; Seeber S; Kettenberger H; Breuer S; Killian T; Schäfer W; Brinkmann U
    Int J Mol Sci; 2015 Nov; 16(11):27497-507. PubMed ID: 26593903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface.
    Lewis SM; Wu X; Pustilnik A; Sereno A; Huang F; Rick HL; Guntas G; Leaver-Fay A; Smith EM; Ho C; Hansen-Estruch C; Chamberlain AK; Truhlar SM; Conner EM; Atwell S; Kuhlman B; Demarest SJ
    Nat Biotechnol; 2014 Feb; 32(2):191-8. PubMed ID: 24463572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
    Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform.
    Pekar L; Busch M; Valldorf B; Hinz SC; Toleikis L; Krah S; Zielonka S
    MAbs; 2020; 12(1):1812210. PubMed ID: 32887531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules.
    Seifert O; Rau A; Beha N; Richter F; Kontermann RE
    MAbs; 2019 Jul; 11(5):919-929. PubMed ID: 30951400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies.
    Shen J; Vil MD; Jimenez X; Zhang H; Iacolina M; Mangalampalli V; Balderes P; Ludwig DL; Zhu Z
    J Immunol Methods; 2007 Jan; 318(1-2):65-74. PubMed ID: 17126853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction and production of an IgG-Like tetravalent bispecific antibody, IgG-single-chain Fv fusion.
    Lu D; Zhu Z
    Methods Mol Biol; 2014; 1060():185-213. PubMed ID: 24037843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VH and VL Domains of Polyspecific IgM and Monospecific IgG Antibodies Contribute Differentially to Antigen Recognition and Virus Neutralization Functions.
    Pasman Y; Kaushik AK
    Scand J Immunol; 2016 Jul; 84(1):28-38. PubMed ID: 27104652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies.
    Kipriyanov SM; Moldenhauer G; Braunagel M; Reusch U; Cochlovius B; Le Gall F; Kouprianova OA; Von der Lieth CW; Little M
    J Mol Biol; 2003 Jun; 330(1):99-111. PubMed ID: 12818205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.